Tizanidine Tablet
Product Images NDC 64980-659

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 64980-659). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (3edde2f7 87aa 4ae9 Af8a Ddb012ff4862 01)

Chemical structure diagram of tizanidine hydrochloride showing the molecular arrangement including a chlorinated ring and heterocyclic components.*

FDA Label Image

Image (3edde2f7 87aa 4ae9 Af8a Ddb012ff4862 02)

A line graph showing plasma tizanidine concentration (ng/mL) over 24 hours post-dosing for 2 mg and 4 mg doses of tizanidine tablets and capsules taken with and without food. The graph compares four conditions, illustrating absorption and elimination profiles after oral administration.*

FDA Label Image

Image (3edde2f7 87aa 4ae9 Af8a Ddb012ff4862 03)

A line graph showing improvement in Ashworth Score over time post-dose (0 to 6 hours) comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph illustrates higher improvement levels for 16 mg tizanidine than 8 mg and placebo, with error bars shown for data variability.*

FDA Label Image

Image (3edde2f7 87aa 4ae9 Af8a Ddb012ff4862 04)

A line graph depicting improvement in Ashworth Score over three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Two groups are shown: tizanidine (mean dose 28.8 mg) with a greater improvement (lower scores) and placebo with minimal change, including error bars for variability.*

FDA Label Image

Image (3edde2f7 87aa 4ae9 Af8a Ddb012ff4862 05)

The label for Tizanidine Tablets, USP 2 mg oral tablets by Rising Pharmaceuticals features a blue and white design. It states each tablet contains 2 mg of tizanidine base and that 30 tablets are included. The label includes storage instructions, a warning that these tablets are not interchangeable with Zanaflex Capsules, and identifies Graviti Pharmaceuticals Pvt. Ltd. as the manufacturer in India and Rising Pharma Holdings, Inc. as the distributor in New Jersey, USA.*

FDA Label Image

Image (3edde2f7 87aa 4ae9 Af8a Ddb012ff4862 06)

Label for Tizanidine Tablets, USP 4 mg oral tablets, with a quantity of 30 tablets per container. The label includes the NDC number 64980-659-03 and shows the Rising Pharmaceuticals logo. It states the product is prescription only (Rx only) and provides storage instructions. The label identifies the manufacturer as Graviti Pharmaceuticals Pvt. Ltd., India, and the distributor as Rising Pharma Holdings, Inc., East Brunswick, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.